A total of 35 percent of cancers diagnosed after second-opinion review were not initially detected in the original interpretation.
Interpretations of suspicious breast imaging exams change almost half the time with a second opinion, according to a study published in the Journal of the American College of Radiology.
Researchers from the Memorial Sloan Kettering Cancer Center in New York City, N.Y., performed a retrospective review to determine the effect of subspecialty review of breast imaging on patients without a diagnosis of breast cancer who self-referred for a second opinion.
The researchers reviewed 415 breast imaging studies submitted for second-opinion review by 245 patients, excluding cases without follow-up or change in original BI-RADS 0 assessment. In total, 147 patients with 176 lesions were included in the study. Original and second-opinion interpretations and recommendations were compared with histopathology or follow-up imaging.
The results showed 96 of 176 (55 percent) lesions were reported as suspicious in the original interpretation. Second-opinion reviews were discordant with the original interpretation in 82 of 176 (47 percent) lesions:
• 24 of 96 (25 percent) lesions were downgraded, originally reported as suspicious to benign or probably benign, removing the need for biopsies
• 31 of 80 (39 percent) lesions were upgraded, originally reported as benign or probably benign to suspicious
A total of 87 lesions were biopsied yielding malignancy in 23 (26 percent) biopsies; 28 of 87 (32 percent) biopsies performed were recommended after second-opinion review, with 8 of 28 (29 percent) of these biopsies yielding cancer. Eight of 23 (35 percent) cancers detected represented malignancy not initially detected in the original interpretation.
The researchers concluded second-opinion reviews of suspicious findings, even before a diagnosis of breast cancer, often led to a change in the interpretations. While 25 percent of originally recommended biopsies were averted, cancer was detected in 29 percent of additional biopsies recommended and 35 percent of cancers diagnosed after second-opinion review were not initially detected in the original interpretation.
Mammography News: FDA Grants Expanded 510(k) Clearance for AI-Powered SmartMammo Dx DBT Software
November 29th 2024Originally cleared by the FDA in 2021, the SmartMammo Dx software for digital breast tomosynthesis (DBT) can now be utilized with the Senographe Pristina mammography systems from GE HealthCare.
Ultrasound Device Garners FDA De Novo Nod for Kidney Stone Clearance
November 14th 2024Emerging research demonstrated that the Stone Clear device, which facilitates post-lithotripsy clearance of kidney stone fragments, led to a 70 percent lower risk of relapse in comparison to observation in a control group.
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.